Our locations are open for all appointments and procedures, including COVID-19 testing. Schedule an appointment online or call your doctor’s office. Patients may now be accompanied by visitors. Read our updated visitor policy.

Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Lila Nachtigall, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
View Locations

Conditions and Treatments

Education and Training
  • Residency, NYU Medical Center, Medicine (Internal), 1964
  • Fellowship, NYU Medical Center, Endocrinology, 1963
  • MD from New York Medical College, 1960

Is this your profile?

Edit profile

Locations and Appointments

251 East 33rd Street, 5th Floor
New York, NY 10016

Interests

estrogen replacement therapy

Research Summary

Over the past 20 years Lila E. Nachtigall, M.D. has been involved in three areas of investigation. These include: 1) evaluating whether estrogen replacement therapy (ERT) reduces the risk of coronary heart disease and other cardiovascular in women; 2) determining whether estrogen replacement alone or estrogen progesterone replacement reduces the incidence of osteoporosis-related fractures and hip fractures; and 3) whether ERT increases the risk of endometrial cancer and whether progestin and estrogen replacement therapies (PERT) increase breast cancer risk.

Studies in these specific areas have been ongoing at NYU Medical Center since 1967. Dr. Nachtigall conducted a comprehensive ten year prospective double blind placebo controlled study of estrogen replacement therapy and the relationship to carcinoma, cardiovascular disease, and osteoporosis in a sample of hospitalized women. From the 300 women recruited, 168 were followed as matched pairs. This study was the first to demonstrate the increased survival of patients on ERT, of lipid patterns as a significant risk factor, and of a reduction in breast cancer incidence in treated patients as compared to the controls. Moreover, a ten year follow-up with single photon densitometer measurements found continued increase in bone density in treated women who had their last menstrual period within three years or less, while those on placebo continued to lose bone. In addition, treated women who had their last menstrual period more than three years previously, kept their bone at a steady level, while their placebo controlled matched pairs continued to lose bone. Dr. Nachtigall subsequently conducted a 22 year follow-up on these studies, losing only five patients to follow-up or breast cancer.

Studies are continuing to address such issues as the efficacy of transdermal versus oral estrogen, the use of progesterone in prevention of endometrial cancer, the ability to decrease the side effects of progesterone therapy and on cardiovascular disease in older women, with and without hormones.

Academic Contact

Academic office

540-562 First Avenue

Tenth Floor

New York, NY 10016

Phone

212-263-6361

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

Read All Publications (86)